Until efficacy and safety are confirmed in prospective trials, doxapram should be used with caution.
S. A. Prins, S. J. A. Pans, M. M. van Weissenbruch, F. J. Walther, S. H. P. Simons 2013, 'Doxapram Use for Apnoea of Prematurity in Neonatal Intensive Care', International Journal of Pediatricshttp://dx.doi.org/10.1155/2013/251047. Retrieved from DOAJ CC BY 4.0 (https://creativecommons.org/licenses/by-sa/4.0/legalcode)
64.8% of patients did not need intubation after doxapram.
S. A. Prins, S. J. A. Pans, M. M. van Weissenbruch, F. J. Walther, S. H. P. Simons 2013, 'Doxapram Use for Apnoea of Prematurity in Neonatal Intensive Care', International Journal of Pediatricshttp://dx.doi.org/10.1155/2013/251047. Retrieved from DOAJ CC BY 4.0 (https://creativecommons.org/licenses/by-sa/4.0/legalcode)
No patients died during doxapram therapy.
S. A. Prins, S. J. A. Pans, M. M. van Weissenbruch, F. J. Walther, S. H. P. Simons 2013, 'Doxapram Use for Apnoea of Prematurity in Neonatal Intensive Care', International Journal of Pediatricshttp://dx.doi.org/10.1155/2013/251047. Retrieved from DOAJ CC BY 4.0 (https://creativecommons.org/licenses/by-sa/4.0/legalcode)